EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

Arcutis Biotherapeutics, Inc. (ARQT) had EBITDA of $18.96M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$129.50M
Net Income	$17.39M
Cost of Goods Sold	$11.69M
Gross Profit	$117.81M
Operating Expenses	$111.12M
Operating Income	$18.39M
Non-Operating Income/Expense	$-0.52M
Pre-Tax Income	$17.86M
Normalized Pre-Tax Income	$17.86M
Income after Taxes	$17.39M
Income from Continuous Operations	$17.39M
Consolidated Net Income/Loss	$17.39M
Normalized Income after Taxes	$17.39M
EBIT	$18.39M
EBITDA	$18.96M
Weighted-Average Shares Outstanding (Basic)	127.23M
Weighted-Average Shares Outstanding (Diluted)	127.23M
Earnings per Share (EPS) (Basic)	$0.14
Earnings per Share (EPS) (Diluted)	$0.14
Balance Sheet Financials
Current Assets	$411.23M
Property, Plant, and Equipment	$1.04M
Long-Term Assets	$21.74M
Total Assets	$432.97M
Current Liabilities	$129.84M
Long-Term Debt	$107.96M
Long-Term Liabilities	$113.66M
Total Liabilities	$243.49M
Common Equity	$189.48M
Tangible Shareholders Equity	$174.67M
Shareholders Equity	$189.48M
Common Shares Outstanding	123.33M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-5.62M
Cash Flow from Investing Activities	$-30.25M
Cash Flow from Financial Activities	$6.97M
Beginning Cash	$71.95M
End Cash	$43.22M
Increase/Decrease in Cash	$-28.74M
Stock-Based Compensation	$40.36M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.17
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.36
Debt to Equity Ratio	0.57
Gross Margin	90.97%
Operating Margin	14.20%
EBIT Margin	14.20%
EBITDA Margin	--
Pre-Tax Profit Margin	13.80%
Profit Margin	13.43%
Free Cash Flow	$-6.31M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.30
Inventory Turnover	0.52
Receiveable Turnover	0.89
Days Sales in Receivables	101.62
Return on Equity	9.18%
Return on Tangible Equity	9.96%
Return on Assets	4.02%
Return on Investments	5.85%
Book Value Per Share	$1.54
Free Cash Flow per Share	$-0.05
Operating Cash Flow per Share	$-0.04

Data from Zacks Investment Research, Inc.